What is Roivant Sciences's market cap?

Roivant Sciences (ROIV) has a market capitalization of $26.5B and trades on NASDAQ.

What is Roivant Sciences's revenue and profitability?

Roivant Sciences generated $8.3M in trailing twelve-month revenue, representing a net margin of -6079.9%, with free cash flow of -$758.6M. These figures are based on the Q1 2026 filing.

Who are Roivant Sciences's competitors?

Roivant Sciences's key competitors include Amgen, Moderna, BioNTech, and others. These companies compete in similar markets and product categories.

Who does Roivant Sciences partner with?

Roivant Sciences's notable partners include Pfizer, HanAll Biopharma, Bayer, and others.

What subsidiaries does Roivant Sciences have?

Roivant Sciences's subsidiaries include Immunovant, Priovant Therapeutics, Pulmovant, and others.

Where is Roivant Sciences headquartered?

Roivant Sciences is headquartered in United Kingdom and employs approximately 908 people. It has been publicly traded since 2021.

Roivant Sciences

ROIV

Roivant is a biopharmaceutical company that utilizes a decentralized 'Vant' model to accelerate the development and commercialization of transformative medicines.

Market cap

$26.48B+237%

Revenue$8.3M-71.6%

Free cash flow-$758.6M+10.1%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q4 2026 report

May 20, 2026

Revenue$2.5MMiss by $894.5K EPS-$0.36Miss by $0.10

Read the full report

Next report

Aug 10, 2026 (in a month)

Revenue estimate$2.1M

EPS estimate-$0.33

Financials

Q4 2025

Income statement

See full

Revenue$2.5M-66.7%

Balance sheet

See full

Cash & equivalents$1.4B+1,411%

Total debt$107.4M+7.3%

Total equity$4.5B-3.4%

Total assets$5.7B+5.0%

Cash flow

See full

Operating cash flow-$163.8M+5.1%

CapEx$1.3M+55.5%

Free cash flow-$165.1M+4.8%

Valuation & ratios

Valuation

See full

Market cap$26.48B+237%

Enterprise value$25.16B+244%

P/S3,205.4×+2,891×

Profitability

See full

FCF margin-9,183.5%-17,093pp

Returns & leverage

See full

Debt / equity0×0.0×

Current ratio18.4×-15.1×

Segments

By segment

See full

Reportable Segment$2.5M-66.7%

Competitors

By market cap

Amgen$196.25B+24.6%

Moderna$30.4B+163%

Roivant Sciences$26.5B+263%

Compass Therapeutics, Inc.$416.0M+14.0%

Voyager Therapeutics, Inc.$222.4M+32.2%

ABVC BioPharma, Inc.$37.7M-44.4%

HIN

Vyome Holdings, Inc.$15.7M—

Aptevo Therapeutics$4.9M-99.2%

By revenue growth

Amgen+9.1%

Moderna-30.0%

Roivant Sciences-71.6%

By net margin

Amgen20.96%+3.6pp

Moderna-143.55%-37.9pp

Roivant Sciences-6,079.94%—

Profile

Roivant is a biopharmaceutical company that utilizes a decentralized 'Vant' model to accelerate the development and commercialization of transformative medicines. The company advances a diverse pipeline of small molecules and biologics across immunology, inflammation, and pulmonary hypertension by creating nimble, subsidiary-focused business units. Beyond therapeutics, Roivant incubates discovery-stage companies and health technology startups to complement its core drug development engine.

Competitive position

Roivant maintains a unique position through its decentralized Vant model, which combines the focus of a biotech startup with the scale and resources of a large pharmaceutical firm.

GeographiesUnited States, European Union, United Kingdom, Japan

Customer segmentsHealthcare Providers, Pharmaceutical Companies, Government Health Programs

Business modelResearch and Development, Licensing and Royalties, Venture Studio

SuppliersAcademic Research Institutions, Contract Manufacturing Organizations, Contract Research Organizations, Pharmaceutical Licensors

CustomersWholesale Distributors, Specialty Pharmacies, Hospitals, Government Payors

CountryUnited Kingdom

Listed2021

Employees908.0

CEOMatthew Gline

SectorHealthcare

IndustryBiotechnology

Websiteroivant.com

FilingsSEC EDGAR

Ask your AI about Roivant Sciences.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Roivant Sciences's market cap?: Roivant Sciences (ROIV) has a market capitalization of $26.5B and trades on NASDAQ.
What is Roivant Sciences's revenue and profitability?: Roivant Sciences generated $8.3M in trailing twelve-month revenue, representing a net margin of -6079.9%, with free cash flow of -$758.6M. These figures are based on the Q1 2026 filing.
Who are Roivant Sciences's competitors?: Roivant Sciences's key competitors include Amgen, Moderna, BioNTech, and others. These companies compete in similar markets and product categories.
Who does Roivant Sciences partner with?: Roivant Sciences's notable partners include Pfizer, HanAll Biopharma, Bayer, and others.
What subsidiaries does Roivant Sciences have?: Roivant Sciences's subsidiaries include Immunovant, Priovant Therapeutics, Pulmovant, and others.
Where is Roivant Sciences headquartered?: Roivant Sciences is headquartered in United Kingdom and employs approximately 908 people. It has been publicly traded since 2021.